Key Takeaways Enhertu-Perjeta gets FDA nod as first-line option for unresectable or metastatic HER2-positive breast cancer.Phase III DESTINY-Breast09 showed PFS of 40.7 months vs 26.7 months, reducing progression risk by 44%.Following approval, Daiichi is entitled to receive a $150 million milestone under the Enhertu collaboration.AstraZeneca PLC (AZN) and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody-drug conjugate (ADC), Enhertu, for first-line use i ...